Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

LV: Everolimus Eluting Stents vs. Coronary Artery Bypass Graft

Original Title: Revascularization in Patients with Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction: Everolimus Eluting Stents vs Coronary Artery Bypass Graft Surgery

Reference: Bangalore et al. Circulation. 2016 May 5. Epub ahead of print.

 

Courtesy of Dr. Guillermo Migliaro.

 

Guidelines recommend coronary artery bypass graft surgery (CABG) over percutaneous coronary intervention (PCI) for multivessel disease and severe left ventricular (LV) systolic dysfunction. However, to date, there are no randomized studies comparing both strategies in these patients, since, in general, LV systolic dysfunction will automatically exclude them.

The aim of this study is to compare the clinical efficacy of CABG vs. PCI in patients with multivessel and severe LV dysfunction.

This is an observational retrospective study including patients from the New York State surgery and PCI registries (n= 4616) with multivessel disease (except those with left main lesion) and ejection fraction lower than 35% that had undergone PCI with everolimus eluting stents or CABG. Patients included in the study were matched using propensity score (n= 1063 in each group). Primary end point was all cause mortality at long term and secondary end points were acute myocardial infarction (AMI), stroke and repeat revascularization.

Mortality at 30 days was not significantly different between the groups (HR=0.62; 95% CI 0.31-1.24; p=0.17) neither was AMI (HR=1.60; 95% CI 0.52-4.89; p=0.41).

PCI presented lower risk of stroke (0.1% vs 1.8%; HR=0.05; 95% CI 0.01-0.39; p=0.004).

At long term, (median 2.9 years) mortality was similar in both groups, with no statistically significant differences (HR=1.01; 95% CI 95% 0.81-1.28; p=0.91). PCI presented higher risk of AMI (HR=2.16; 95% CI 1.42-3.28; p=0003) only in the subgroup of patients which had not received complete revascularization (interaction test p=0.002). PCI also showed higher risk of repeat revascularization (HR=2.54; 95%IC 95% 1.88-3.44 p<0.0001) and lower risk of stroke (HR 0.57; 95% CI 0.33-0.97; p=0.04).

 

Conclusion

In patients with multivessel disease and depressed systolic function, PCI with everolimus eluting stents have a survival rate comparable to that of surgery. PCI presented higher risk of AMI in the subgroup of patients with incomplete revascularization and lower risk of stroke, compared to CABG.

 

Editorial Comment

This is an observational study (though with perfectly balanced groups), which is common to studies that are not randomized.

It does not take into account the anatomical features of coronary angiographies (such as the Syntax score) or an estimation of clinical risk (such as STS or EuroScore)

Neither does it inform on procedure characteristics, number of implanted stents, the use of coronary intravascular ultrasound or optical coherence tomography for procedure optimization, or the number of arterial and venous grafts. It does not report the use of FFR as a guide (functional revascularization) or the presence or absence of feasibility. Neither does it specify the antiplatelet regime or its duration.

Since there is no evidence from randomized studies, the present study is a hypothesis generator and should be corroborated by further research on a large scale.

 

Courtesy of Dr. Guillermo Migliaro.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...